摘要
目的:了解LKB1蛋白在肺腺癌组织中表达的临床意义。方法:应用免疫组化法检测62例肺腺癌组织中LKB1蛋白表达情况。结果:LKB1蛋白在肺腺癌细胞及正常肺支气管上皮均有表达,弥漫性分布于细胞质,细胞核亦有表达。肺腺癌组织中LKB1蛋白表达的阴性率为38.7%(24/62)。LKB1的表达与肺腺癌TNM分期中的淋巴结转移(N)及临床分期有显著的相关性,χ2=10.620,P=0.014;χ2=18.635,P=0.000。LKB1蛋白阴性组预后较差,中位生存期为15个月,而LKB1阳性组的中位生存时间为29个月,两者比较差异有统计学意义,χ2=15.350,P=0.000。结论:LKB1蛋白表达下降与肺腺癌发生淋巴结转移相关,是肺腺癌预后不良的风险因素之一。
OBJECTIVE： To study the expression of LKB1 protein and its clinical significance in lung adenocarcinomas. METHODS： Immunohistochemical staining was performed with LKB1 antibody to the surgically resected tissue samples from 62 patients with lung adenocarcinoma. RESULTS： The negative rate of the expression LKB1 protein in lung adenocinoma was 38.7% （24/62）. The expression LKB1 protein was associated with the extent of lymph node metastasis （ X^2 = 10. 620, P = 0. 014） and clinical stages,X^2 = 18. 635 ,P=0. 000. The median survival time was 15 months in the LKB1 protein negative expression group, however, 29 months in the LKB1 protein positive expression group,X^2 = 15. 350,P=0. 000. CONCLUSION： Loss LKB1 expression in lung adenocarcinoma may contribute to the lymph node metastasis, and this may be a risky factor for the prognosis of patients with lung adenocarcinoma.
出处
《肿瘤防治杂志》
2005年第17期1281-1284,共4页
China Journal of Cancer Prevention and Treatment
基金
国家自然科学基金(30270590)
关键词
肺肿瘤
腺癌
基因
抑制
肿瘤
预后
免疫组织化学
lung neoplasms
adenocarcinoma
genes, suppressor, tumor
prognosis
immunohistochemistry
